2020
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Weintraub D, Caspell‐Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M, Initiative P. Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals Of Clinical And Translational Neurology 2020, 7: 449-461. PMID: 32285645, PMCID: PMC7187707, DOI: 10.1002/acn3.51022.Peer-Reviewed Original ResearchConceptsParkinson's disease participantsNeuropsychiatric symptomsParkinson's diseaseHealthy controlsCognitive impairmentMedication useYear 5Anticholinergic medication useCross-sectional prevalenceParkinson's disease patientsHypnotic useDisease patientsNeuropsychiatric featuresDisease onsetAnnual visitsSymptomsDisorder subtypesAbsolute prevalenceDiseaseTime pointsPrevalenceBaselineImpairmentParticipantsOnset
2017
Cognition and the course of prodromal Parkinson's disease
Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition and the course of prodromal Parkinson's disease. Movement Disorders 2017, 32: 1640-1645. PMID: 29063713, PMCID: PMC5722226, DOI: 10.1002/mds.27189.Peer-Reviewed Original ResearchConceptsSpeed/attentionCognitive declineProdromal participantsBaseline neuropsychological test performanceExecutive function/Role of cognitionNeuropsychological test performanceFuture cognitive declineBaseline cognitive scoresCognitive domainsGlobal cognitionBaseline cognitionCognitive scoresCognitionTest performanceFuture declinePD-convertersDopamine systemHyposmic individualsProdromal PDLongitudinal changesFunction/ParticipantsDopamine transporter bindingIndividuals
2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis
Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research 2012, 206: 195-199. PMID: 23159196, PMCID: PMC3600156, DOI: 10.1016/j.psychres.2012.10.013.Peer-Reviewed Original ResearchConceptsClinical high riskCHR individualsComprehensive cognitive test batteryCognitive test batteryCognitive impairmentFuture longitudinal researchCognitive functioningCognitive performanceCognitive testsTest batteryLongitudinal researchCognitionPoor performanceLongitudinal changesPsychosisIndividualsParticipantsImpairmentBaseline participantsFunctioningPerformanceBatteriesResearchProdrome
2011
The Parkinson Progression Marker Initiative (PPMI)
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Klinik P, Sherer T, Frasier M, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Zhang Y, Toga A, Crawford K, Ansbach A, De Blasio P, Piovella M, Trojanowski J, Shaw L, Singleton A, Hawkins K, Eberling J, Brooks D, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Delgado H, Jankovic J, Hunter C, Stern M, Tran B, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Lang E, Shill H, Obradov S, Fernandez H, Winters A, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, Gerstenhaber M, Brooks D, Malloy S, Barone P, Longo K, Comery T, Ravina B, Grachev I, Gallagher K, Collins M, Widnell K, Ostrowizki S, Fontoura P, Ho T, Luthman J, van der Brug M, Reith A, Taylor P, Initiative T. The Parkinson Progression Marker Initiative (PPMI). Progress In Neurobiology 2011, 95: 629-635. PMID: 21930184, PMCID: PMC9014725, DOI: 10.1016/j.pneurobio.2011.09.005.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCohort StudiesDiagnostic ImagingDisease ProgressionFemaleHumansInternational CooperationMaleMulticenter Studies as TopicParkinson DiseaseConceptsParkinson's Progression Markers InitiativeProgression Markers InitiativeProgression biomarkersCerebrospinal fluidMulti-center studyTherapeutic trialsPPMI cohortHealthy subjectsBiomarker assessmentClinical sitesStudy databaseReview CommitteeDisease etiologyLongitudinal collectionComprehensive observationalBiomarkersStudy dataAcquisition protocolsLikelihood of successEtiologyCohortBlood
2007
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population
Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. The British Journal Of Psychiatry 2007, 191: 355-356. PMID: 17906248, DOI: 10.1192/bjp.bp.106.031195.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersTime-dependent Cox regression analysisCox regression analysisMedication-free intervalOlanzapine treatmentPlacebo groupPharmacological treatmentProdromal symptomsRisk factorsProdromal populationSpeech illusionsDisordersRegression analysisYear 2TreatmentSignificant interactionYear 1Symptoms